The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Should ropeginterferon become SoC for all patients with low-risk PV?

Jun 16, 2020

During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to Tiziano Barbui, L'ospedale Papa Giovanni XXIII, Bergamo, IT. We asked: Should ropeginterferon become standard of care for all patients with low-risk polycythemia vera (PV)?

Hematocrit control is vital in patients with PV, but is phlebotomy necessary to maintain hematocrit target levels? The monopegylated IFNα-2b, ropeginterferon, may reduce the need for phlebotomy. Results from the randomized phase II study comparing ropeginterferon with phlebotomy for the treatment of low-risk PV will be presented at this year's EHA meeting.

Should ropeginterferon become SoC for all patients with low-risk PV?